The study also revealed, through 48 h continuous glucose monitoring, that DM1 patients exhibit distinct glucose fluctuation patterns, suggesting that DPP-4 inhibitors may help improve these fluctuations. Here, DPP4 is linked to myotonic dystrophy type 1.